Advertisement

Topics

Alexion signs funding deal with NICE and NHS England for Strensiq

05:31 EDT 5 Jul 2017 | Pharmaceutical Business Review

Alexion Pharmaceuticals has signed a national funding agreement with the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England based on a Managed Access Agreement (MAA), which provides access to Strensiq (asfotase alfa) for patients in England with pediatric-onset hypophosphatasia (HPP), regardless of their current age.

Original Article: Alexion signs funding deal with NICE and NHS England for Strensiq

NEXT ARTICLE

More From BioPortfolio on "Alexion signs funding deal with NICE and NHS England for Strensiq"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...